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Malaria was the first parasitic infection clearly rec-
ognized as responsible for renal disease in tropical areas.
Renal manifestations are mainly associated with two para-
sites: (i) Plasmodium malariae, which usually gives rise
to an immune-complex mediated mesangiocapillary glom-
erulonephritis (GN) several weeks after the onset of symp-
toms; and (ii) Plasmodium falciparum, which can cause
different types of renal alterations, ranging from asymp-
tomatic disorders to acute renal failure1–2. Here we de-
scribe an unusual pattern of GN in an Ivorian girl with P.
falciparum infection, and its unexpected response to
artemether therapy.
Case report
An Ivorian 13-yr old girl was admitted to a peripheral
hospital for a 15-day history of fever, asthenia, and a weight
loss of about 7 kg in the past four months. She had arrived
in Italy one month before; at 10-yr of age she had uncom-
plicated malaria. Clinical examination revealed mild sple-
nomegaly and macroscopic haematuria with laboratory
findings, severe anaemia (Hb = 7.2 g/dl), elevation of C-
reactive protein (17.6 mg/dl, normal value (n.v.) <0.5) and
erythrocyte sedimentation rate (112 mm/h, n.v. <20). As
malaria testing was found positive for P. falciparum
parasitaemia (4%), she was given oral atovaquone-
proguanil for three days with resolution of parasitaemia.
However, the girl developed a progressive impairment of
renal function (creatinine level up to 1.49 mg/dl, n.v. 0.4–
1.1, and proteinuria/creatinuria ratio 1.2, n.v. <0.2) with
persistence of fever and increased inflammatory indices.
She was thus referred to our Department for further inves-
tigations: serum creatinine increased up to 2.1 mg/dl and
proteinuria/creatinuria ratio up to 2.5; estimated glomeru-
lar filtration rate (eGFR) went down to 30 ml/min/1.73 m2
(according to the Schwartz’s formula). She had hypergam-
ma-globulinemia (IgG 1933 mg/dl), decreased albumin
(down to 2.69 mg/dl, n.v. 3.92–5.18), but no alteration in
lipid profile and in complement components. No hyper-
tension or evident peripheral edema was noted. Abdomen
ultrasound imaging revealed kidneys’ enlargement (12
cm the right and 11.3 cm the left), increased parenchymal
echogenicity and lump profile.
Malarial parasitaemia was repeated in many occasions
and was persistently negative; however, considering the
previous malaria as the sole identified agent responsible
for renal impairment (other infectious agents, lympho-
proliferative disorders and iatrogenic causes of renal dam-
age were sorted out), the patient was empirically retreated
with oral artemether plus mefloquine. This was discon-
tinued after Day 1 for intolerance (nausea and vomiting),
and artemether was thus administered for 7 days: the pa-
tient had rapid improvement of clinical conditions, nor-
malization of body temperature, and no further deteriora-
tion in renal function, but decrease in creatinine levels
(1.7 mg/dl) and macroscopic haematuria were noticed.
On the ultrasound-guided biopsy performed to clarify
renal disease, the unexpected pattern of rapidly progres-
sive GN was observed instead of the chronic membra-
nous GN typically associated with P. falciparum
infection. Florid “crescents” were found in 10 out of 34
glomeruli (30%), with fibrotic evolution in five glom-
eruli and massive extracapillary proliferation. Inflamma-
tory cells infiltrated the Bowman’s capsule, immunoglo-
bulins G and C3 deposits were evident along the basement
membrane and in subepithelial spaces; haematic dross and
cellular cylinders were detected in tubular lumens. Given
the poor prognosis associated with this histological pat-
tern, the girl started a massive immunosuppressive therapy
(10 mg/kg iv methylprednisolone for three doses, shifted
to 1 mg/kg/day oral prednisone, and 2 mg/kg/day cyclo-
phosphamide for eight weeks) associated with eight plas-
mapheresis. After three weeks, renal function was con-
siderably improved, and at last check 18-months later,
the girl maintained a normal renal function, with serum
creatinine 0.8 mg/dl, no evident proteinuria or haematuria,
and a proteinuria/creatinuria ratio of 0.18.
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DISCUSSION
Renal impairment is listed among the severe compli-
cations of P. falciparum infection3: it usually turns up in
the context of high parasitaemia (> 5%), and it is mostly
related to acute tubular necrosis (ATN)1, 4–5. Plasmodium
falciparum can occasionally trigger a nephritic or
nephrosic syndrome commonly reversible in 2–6 weeks
after parasitic eradication2. These clinical manifestations
are usually sustained by membranous GN histological
pattern, defined by mesangial proliferation and basement
membrane thickening at microscope, subendothelial
and mesangial electron-dense deposits made up by
IgM, IgG3 and C3 at electron microscopy, suggesting
deposition of circulating immune complexes1–2, 5. Hypo
complementemia due to complement cascade activation
is common, as well as hypergammaglobulinemia due to
polyclonal B lymphocyte expansion. Therefore, malaria
nephropathy is interpreted as an immune-mediated dis-
ease resulting from immune-complex deposition, activa-
tion of locally marginated mononuclear cells, and release
of inflammation mediators (cytokines, reactive oxygen
intermediates–ROI and nitric oxide–NO) leading to en-
dothelial damage1–2, 5. In our patient, the long exposure
to malarial parasites might have elicited a massive im-
mune response leading to rapidly progressive GN. It’s
the first time that this histological pattern is described in
association with P. falciparum infection. Rapidly progres-
sive GN gives rapid loss of renal function, with a 50%
eGFR decline within three months after onset of symp-
toms: if untreated, it quickly evolves to end-stage renal
disease in 50% of the patients6.
The girl needed an aggressive immunosuppressive
therapy to have renal function recovered. However, her
clinical improvement started with the 7-day course of
artemether therapy, with creatinine levels and macroscopic
haematuria decrease, results already maintained after
artemether suspension. Artemether might have had a “col-
lateral” but significant role in reducing the massive
immune response which led to the rapidly progressive
GN pattern. Several investigations underlined the pos-
sible immunomodulatory effects of artemisinin and its
derivatives, such as a Treg proliferation by Foxp3 up-
regulation and suppression of Th17 pathway that can
diminish immune reactivity and tissue inflammation7.
These effects are potentiated by suppression of NO syn-
thesis and Tumour Necrosis Factor (TNF) down-regula-
tion7–8, usually involved in endothelial cells activation
and damage of malarial disease8. Artemisinin derivates
can also inhibit the binding of Vascular Endothelial
Growth Factor (VEGF) to its receptors and down regu-
late VEGF receptor expression, with inhibition of the
angiogenesis implicated primarily in cerebral malarial
dysfunctions8–9.
In conclusion, renal impairment by P. falciparum in-
fection may be related to an immune-mediated disease
configuring as rapidly progressive GN. The use of
artemisinin derivates can combine an efficient parasitic
eradication to an oxidative stress down-regulation and
effective modulation of massive immune responses to
parasites.
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